$NVO Stock: The Wegovy Pill Turnaround the Market May Be Pricing Too Cheaply

Novo Nordisk went from being the market's favorite obesity company to one of its favorite disappointments. Eli Lilly gained share. U.S. pricing weakened. CagriSema missed its primary head-to-head endpoint. Management guided to an adjusted sales decline in 2026. The stock fell hard enough that the old story of effortless GLP-1 dominance no longer works.

That is exactly why NVO stock is interesting now.

The bull case is not that the bad news was fake. It was real. The bull case is that the market may be pricing Novo Nordisk as if lower prices, stronger competition, and pipeline setbacks permanently destroyed a century-old metabolic-disease franchise. Meanwhile, the company launched the first oral GLP-1 for weight management in the United States, passed three million pill prescriptions in roughly five months, received European approval for the pill, launched a higher-dose Wegovy injection, and secured U.S. approval for the first once-weekly basal insulin for adults with type 2 diabetes.

At the July 23, 2026 close of $48.18, NVO remained far below its prior highs. The stock was no longer priced like an invincible monopoly. My bullish thesis is that Novo does not need to defeat Eli Lilly at every comparison. It needs to stabilize the core business, expand the obesity market with oral treatment, convert approvals into revenue, and prove that 2026 is a reset year rather than the beginning of permanent decline.

The next major checkpoint arrives quickly. Novo Nordisk is scheduled to report first-half 2026 results on August 5.

Investors should not begin this thesis with prescription celebrations. They should begin with the income statement underneath the headlines.

Novo Nordisk reported DKK 96.823 billion of first-quarter sales and DKK 59.618 billion of operating profit. Those reported figures increased 32% and 65% at constant exchange rates, respectively, but they were distorted by a one-time reversal of a provision related to the U.S. 340B Drug Pricing Program.

Excluding that USD 4.2 billion nonrecurring reversal, adjusted sales were DKK 70.063 billion, down 4% at constant exchange rates. Adjusted operating profit was DKK 32.858 billion, down 6%. U.S. adjusted sales declined 11% as lower realized prices outweighed volume growth across the Wegovy portfolio.

That is the real 2026 starting point: volume is growing, but price pressure is strong enough to make underlying revenue shrink.

Management raised its full-year outlook after the quarter, but the range still calls for decline. Adjusted sales growth and adjusted operating-profit growth are each expected to be negative 4% to negative 12% at constant exchange rates. The improvement was only one percentage point at each end from the original negative 5% to negative 13% range.

Calling that guidance bullish would be dishonest. The bullish argument is that the market already knows 2026 is painful and may be underestimating the new products that can reshape the exit rate.

Wegovy tablets became broadly available in the United States on January 5, 2026. During the first quarter, Novo reported about 1.3 million prescriptions and DKK 2.256 billion of pill sales, including the effect of inventory placed with wholesalers and telehealth partners before launch.

By June 2, the company said paid prescriptions had surpassed three million. The second million and third million arrived in a combined ten weeks, faster than the first million's twelve-week path. More than 80% of new-to-brand starts came from people who had not used another GLP-1 during the prior twelve months.

That last number is the strategic center of the thesis. An oral option may expand the treated population instead of merely moving existing injection users from one Novo product to another. Some patients dislike needles. Some primary-care doctors may find a tablet easier to introduce. Distribution through pharmacies and telehealth can make the first conversation feel more familiar.

The pill is not effortless. Oral semaglutide has specific dosing instructions and must still overcome insurance, affordability, adherence, side effects, and competition. Prescription volume does not equal durable, high-margin revenue. Novo has already accepted lower realized prices to expand access.

Still, the first oral GLP-1 approved for weight management is not a cosmetic line extension. It is a new doorway into a market where the majority of eligible patients remain untreated.

On July 15, the European Commission approved Wegovy pill for adults with obesity or qualifying overweight. Novo described it as the first GLP-1 tablet approved for weight management across the European Union. The approval followed the OASIS 4 program, where oral semaglutide 25 milligrams produced approximately 17% mean weight loss compared with about 3% for placebo when combined with lifestyle intervention.

The European Commission also approved a single-dose pen for the 7.2-milligram Wegovy injection. Novo says the higher dose produced roughly 21% mean weight loss in the supporting trial.

Regulatory approval does not guarantee commercial success. European pricing and reimbursement can be more restrictive than in the United States. Country-by-country launches take time. Manufacturing capacity, physician adoption, and budget negotiations can limit the initial ramp.

The strategic point is broader. Novo now has an oral obesity product and a higher-dose injectable platform that can reach patients with different preferences and treatment goals. The company can defend the franchise with a portfolio rather than one weekly dose.

Wegovy pill had already been approved in the United States, United Kingdom, United Arab Emirates, and Bahrain before the EU decision. International launches in the second half of 2026 can begin turning regulatory progress into reported revenue.

Eli Lilly's Zepbound changed the competitive standard by producing greater average weight loss than the original 2.4-milligram Wegovy dose in a head-to-head study. Investors were right to care. In obesity medicine, efficacy affects physician preference, payer negotiations, and brand perception.

Novo responded with Wegovy HD, a 7.2-milligram weekly injection approved by the U.S. Food and Drug Administration in March and launched in April. Novo reports 20.7% mean weight loss in the STEP UP trial under the efficacy estimand, with approximately one-third of participants losing at least 25%.

That was not a head-to-head trial against Zepbound. Investors should not compare separate studies as if the patient populations and methods were identical. Novo's July lawsuit against Lilly over advertising does not settle the scientific debate either.

The investment relevance is more modest and more useful. Novo is no longer defending its obesity franchise with only the older 2.4-milligram dose. Wegovy HD can improve outcomes for patients who need more efficacy and give physicians another step within the same brand.

If HD adoption grows without merely replacing lower-dose Wegovy at worse economics, it can support the franchise. If side effects, payer resistance, or weak demand limit use, the approval will matter less than the headline suggests.

Novo's February REDEFINE 4 result deserves plain language. CagriSema did not meet the primary endpoint of demonstrating non-inferiority to tirzepatide after 84 weeks.

Under the efficacy estimand, participants taking CagriSema lost 23.0% of body weight compared with 25.5% for tirzepatide. Under the treatment-regimen estimand, the results were 20.2% and 23.6%. The market expected Novo's combination of semaglutide and the amylin analogue cagrilintide to close or exceed Lilly's efficacy lead. It did not.

The program still has value. Twenty-three percent weight loss is clinically meaningful. CagriSema could become the first GLP-1 and amylin combination to reach the market. Novo submitted it to the FDA in December 2025 based on the pivotal REDEFINE 1 and REDEFINE 2 studies, with a decision anticipated by late 2026.

The company also plans a higher-dose CagriSema phase 3 trial in the second half of 2026. REDEFINE 11, designed to explore full weight-loss potential, is expected to report in the first half of 2027.

My valuation does not require CagriSema to beat tirzepatide. It does require the product to win meaningful approval, access, and patient demand. Another efficacy or regulatory disappointment would weaken the pipeline argument.

The market understandably focuses on Wegovy and Ozempic. Novo Nordisk's heritage and infrastructure extend across diabetes and other chronic diseases.

In March, the FDA approved Awiqli for adults with type 2 diabetes. It is the first once-weekly basal insulin approved in the United States, reducing planned basal injections from seven per week to one. Novo expects a U.S. launch in the second half of 2026.

Awiqli will not replace the obesity franchise. It shows that Novo can still use its peptide, delivery-device, manufacturing, regulatory, and commercial capabilities beyond GLP-1 weight management. A once-weekly insulin may improve convenience for appropriate patients and reinforce the company's relationships with diabetes specialists.

The company also reported positive phase 3 results for etavopivat in sickle cell disease and continues to develop next-generation obesity candidates, including zenagamtide. Pipeline assets should be treated as probability-weighted options, not guaranteed revenue.

The broader platform matters because a single-product company deserves a lower durability premium than a metabolic-disease specialist with global manufacturing, physician relationships, and a century of experience.

Peptide medicines are difficult to manufacture at enormous scale. Novo's production network, quality systems, fill-finish capacity, and device expertise helped create the modern GLP-1 market. Scarcity once limited growth because the company could not supply all the demand.

Capacity investment can become a moat when demand remains high. A competitor cannot create regulated biological manufacturing overnight. Reliable supply supports pharmacy availability, payer confidence, and physician trust.

The same infrastructure becomes a burden if demand forecasts are wrong or price falls faster than volume rises. Factories require capital. Quality problems can interrupt supply. Regulators can delay lines. New formulations can require different processes. International semaglutide patent expirations can invite lower-cost competition in some markets.

The thesis needs Novo to fill capacity with profitable volume, not merely produce more units. Volume growth that arrives through permanent price compression can make impressive prescription charts coexist with disappointing earnings.

That is why August results matter. I want to see how pill prescriptions translate into revenue, gross margin, and revised full-year expectations.

Novo reported 2025 adjusted diluted earnings of DKK 26.17 per share and ADR. At the July 23 exchange rate near DKK 6.57 per U.S. dollar, that equals roughly $3.98. Against the $48.18 ADR close, the stock traded near 12.1 times that 2025 adjusted earnings base.

Using management's negative 4% to negative 12% adjusted operating-profit guidance as a deliberately rough earnings stress range would put an adjusted earnings base near $3.50 to $3.82 before considering taxes, currency changes, buybacks, and differences between operating profit and net income. That implies approximately 12.6 to 13.8 times the rough range.

This is scenario math, not a precise forecast. The August report will provide better information. The exercise shows that the current valuation is very different from the premium attached to Novo when investors expected uninterrupted obesity dominance.

Novo also paid a total 2025 dividend of DKK 11.70 per share and authorized a DKK 15 billion share-repurchase program for 2026. Dividends and buybacks do not repair a shrinking business, but they show that the company can return capital while funding a large development and manufacturing program.

At this multiple, the stock may work if earnings merely stabilize after 2026. It does not require a return to the old market narrative. That asymmetry is the reason I am interested.

First-half results are scheduled before the Copenhagen market opens on August 5, followed by an earnings call.

The bullish checklist is concrete:

The bearish outcome is equally concrete. Weak pill revenue, worse U.S. net pricing, lower guidance, manufacturing friction, or disappointing uptake could send the stock lower even after the large decline.

I would not treat the report as a coin flip to gamble on. I would treat it as a high-information event. A position entered before earnings should be sized for a gap in either direction. Waiting for the report can reduce event risk at the cost of possibly paying a higher price if the evidence improves.

Eli Lilly is a formidable competitor with Zepbound, Mounjaro, and its own oral obesity program. Better efficacy, stronger execution, or superior payer access can keep shifting share away from Novo.

U.S. pricing pressure is structural, not a one-quarter issue. Novo announced that it plans to reduce the U.S. list prices of several semaglutide products in 2027. Lower list prices can improve access and reduce gross-to-net complexity, but they also make future economics harder to model.

Compounded and alternative GLP-1 products can affect demand, pricing, and public perception. Regulators may restrict them, but the competitive impact does not disappear instantly.

Patent expirations for semaglutide in certain international markets can invite biosimilar or generic competition. Novo can shift toward newer formulations and combinations, but the old molecule will not enjoy identical protection everywhere forever.

The pipeline can disappoint. CagriSema already failed its primary endpoint against tirzepatide. Higher doses can increase side effects as well as efficacy. Regulatory decisions can be delayed or narrowed.

Obesity drugs also face safety, adherence, reimbursement, and political risk. Gastrointestinal side effects are common. Many patients stop therapy. Payers can restrict coverage. Governments can pressure prices. Litigation and advertising disputes can distract management without changing prescribing behavior.

Finally, NVO is a Danish ADR. Currency movement between the krone and dollar can affect U.S. investor returns and reported comparisons.

Those are not remote disclaimers. They are the scoreboard.

The first path is stabilization. If adjusted sales finish 2026 near the better end of guidance and return to growth in 2027, a low-teens earnings multiple can expand without requiring another market mania.

The second path is market expansion. If the pill brings millions of previously untreated patients into GLP-1 therapy, Novo can grow the category even while sharing it with Lilly.

The third path is portfolio depth. Wegovy pill, Wegovy HD, CagriSema, Awiqli, and next-generation candidates can make the company less dependent on one injection and one dose.

The fourth path is international. European and other launches can diversify the U.S. pricing problem, although each market brings its own reimbursement constraints.

The fifth path is cash return. Buybacks can increase per-share value when the stock is genuinely undervalued and the core business stabilizes. They cannot substitute for that stabilization.

None of these paths needs Novo to regain a monopoly. The stock only needs the market to discover that “not first in every comparison” is different from “finished.”

Novo Nordisk is a contrarian stock pick, not a clean momentum trade. The company faces a real earnings reset, a stronger competitor, lower prices, and a pipeline that has already disappointed investors.

It also owns the first oral GLP-1 approved for weight management, a higher-dose Wegovy injection, a global commercial and manufacturing network, the first U.S.-approved once-weekly basal insulin for adults with type 2 diabetes, and a valuation near the low teens on a stressed earnings base.

At $48.18, I am bullish because expectations appear much lower than the company's strategic position. I would not confuse a low multiple with safety, and I would not size the stock like a predictable consumer staple before the August 5 report.

My preferred approach is disciplined accumulation around evidence. If first-half results show that pill demand is becoming durable revenue and management can defend the improved outlook, the 2026 reset may become the foundation of the next chapter. If pricing overwhelms volume and guidance falls again, the market's skepticism will be justified.

Novo does not need to win every round of the obesity war. It needs to prove it can keep compounding while the market finally admits there will be more than one winner.

Novo Nordisk Q1 2026 financial report and raised outlook for source material and context checked before publication.

Novo Nordisk financial-results calendar and August 5 earnings event for source material and context checked before publication.

Novo Nordisk Wegovy pill three-million-prescription milestone for source material and context checked before publication.

Novo Nordisk European approval for Wegovy pill and 7.2 mg injection for source material and context checked before publication.

Novo Nordisk REDEFINE 4 CagriSema results for source material and context checked before publication.

Novo Nordisk 2025 annual report and adjusted earnings for source material and context checked before publication.

NVO July 23, 2026 closing-price reference for source material and context checked before publication.

Disclaimer: MentorSurge is not a financial advisor. This article is educational market commentary, not a recommendation to buy, sell, short, or hold any security. Prices, estimates, and company facts can change quickly. Do your own research and consult a licensed professional before risking money.